H. Lundbeck A/S Board Chair to Step Down in 2027
H. Lundbeck A/S announced that Board Chair Dorothea Wenzel will step down at the 2027 Annual General Meeting. Lars Fruergaard Jørgensen is proposed as the new Chair.
Danish pharmaceutical company H. Lundbeck A/S has announced changes to its Board of Directors. Dorothea Wenzel, the current Chair of the Board, has informed the Board of her intention to step down in connection with the Annual General Meeting in 2027. Wenzel joined the Lundbeck Board in 2021.
The Board intends to appoint Lars Fruergaard Jørgensen as the successor to Wenzel. Jørgensen will join the Board as an observer effective November 10, 2026, prior to his formal election. He brings over 30 years of experience in the pharmaceutical industry, having served as President and CEO of Novo Nordisk from 2017 to 2025.
Lundbeck has undergone a significant transformation in recent years, strengthening its commercial performance and advancing its pipeline. The company is preparing to enter the next phase of its 'Focused Innovator' strategy, aiming for sustainable long-term growth.
Jørgensen, who previously led Novo Nordisk through a period of substantial growth and transformation, is expected to provide significant expertise in global pharmaceutical strategy, innovation, and commercialization. His leadership at Novo Nordisk strengthened its position in diabetes care and obesity treatment.
The company stated that these leadership changes are a natural step as Lundbeck moves into its next strategic phase. Wenzel expressed gratitude for the company's development during her tenure and confidence in its future trajectory.